Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC)

Authors :: Patrizia Giannatempo
Daniele Raggi
Alfonso Marchianò
Filippo de Braud
Elena Farè
Elena Togliardi
Alessandro M. Gianni
Roberto Salvioni
Maria Grazia Daidone
Flavio Crippa
Luigi Mariani
Andrea Necchi
Source :: Journal of Clinical Oncology. 32:TPS4592-TPS4592
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: TPS4592 Background: Progress in developing new effective therapies in advanced and relapsing urothelial cancer has been stagnant in the last few decades and a paradigm shift is desperately needed. ...

Subjects :: Cancer Research
chemistry.chemical_compound
Oncology
chemistry
business.industry
Alisertib
Cancer research
Medicine
Urothelial cancer
Phases of clinical research
Aurora Kinase A
Pharmacology
business

Full Text Access

Tools